Combination therapy with prednisone and isotretinoin in early erythema dyschromicum perstans: A retrospective series

Aisleen Diaz, BS,a Ryan Gillihan, MD,b Kiran Motaparthi, MD,b and Adam Rees, MDC

Ponce, Puerto Rico; Gainesville, Florida, and Panorama City, California

Key words: erythema dyschromicum perstans; hyperpigmentation; isotretinoin; lichen planus pigmentosus; prednisone.

INTRODUCTION

Erythema dyschromicum perstans (EDP) is an acquired hyperpigmentation disorder characterized by asymptomatic, polycyclic, irregularly shaped light lilac-grey patches surrounded by erythematous borders in the early inflammatory stage and subsequently greyish-blue patches in the later ashy stage. Affected areas include the trunk, neck, face, and upper extremities. Mucous membranes are spared.1 EDP occurs in both children and adults, has a higher frequency noted in women, and is common among Latin American, Asian, and Indian populations.2-4 The cause remains largely unknown; however, proton pump inhibitors,5 radioactive contrast,6 hypothyroidism, vitiligo,7 and parasitic and hepatitis C infections,1 are among the associations with EDP.

Histopathologic findings of EDP include vacuolar interface dermatitis and pigment incontinence.4 EDP is histopathologically indistinguishable from lichen planus pigmentosus8; however, distinct clinical characteristics separate the 2 disorders with lichen planus pigmentosus characterized by pruritic, brown-black macules and patches on the face, upper extremities, and flexures with occasional involvement of mucous membranes.1 EDP is cosmetically disfiguring and poses as a therapeutic challenge. Multiple treatments have been proposed that show inconsistent efficacy. Among these are topical steroids, tretinoin, hydroquinone, clofazimine, dapsone, lasers, and narrow-band ultraviolet light B phototherapy.4

A single case is reported each for the use of isotretinoin9 and prednisone.10 In this case series of 4 adult patients with EDP, we report that a combined treatment regimen of prednisone and isotretinoin initiated in the early inflammatory stage leads to rapid resolution of the erythematous border, arrest of progression, and clearance of the hyperpigmentation.

CASES

Case 1

A 54-year-old Hispanic woman with a history of hypothyroidism presented with polycyclic light grey patches with a surrounding erythematous border on the shoulders, arms, forearms, and chest (Fig 1, A). A skin biopsy was consistent with EDP (Fig 1, D). The patient started topical triamcinolone 0.1% cream daily in conjunction with a 3-week prednisone taper as follows: 60 mg/d for 1 week followed by 40 mg/d for 1 week, followed by 20 mg/d for 1 week. Following the prednisone taper, marked improvement of the surrounding erythematous borders were noted (Fig 1, B). In addition to the prednisone, the patient was also started on isotretinoin, which was gradually tapered over 5 months as follows: 40 mg/d for 1 month, followed by 20 mg/d for 3 months, followed by 10 mg/d for 1 month. When
therapy was completed, the patient showed substantial improvement with nearly complete resolution. At 10-month follow up, there was no evidence of disease recurrence (Fig 1, C). However, at the 16-month follow-up the patient had mild relapse on the bilateral legs; the prednisone taper and isotretinoin were restarted with improvement already evident after 4 weeks of retreatment.

Case 2
A 47-year-old Hispanic woman with no medical history presented with multiple irregularly shaped light gray-to-lilac patches with surrounding erythematous borders on the arms, forearms, and neck (Fig 2, A). The patient was started on topical halobetasol 0.05% ointment daily in conjunction with a 3-week prednisone taper as follows: 60 mg/d for 1 week, followed by 40 mg/d for 1 week, followed by 20 mg/d for 1 week. After 3 weeks, the patient showed marked improvement with complete resolution of erythematous borders and improvement of the hyperpigmentation (Fig 2, B). Nine months later, the patient presented to clinic with relapsed disease. The 3-week prednisone taper was restarted, which again led to significant improvement, so she was transitioned to isotretinoin, 40 mg/d, which was tapered over the next 4 months as follows: 40 mg/d for 1 month, followed by 20 mg/d for 2 months, followed by 10 mg/d for the final month. Upon completion of treatment, the patient had sustained improvement without disease recurrence at 24 months.

Case 3
A 54-year-old Hispanic woman with a history of Sjogren syndrome and fibromyalgia presented with multiple ill-defined gray-to-blue patches on the volar aspects of her bilateral upper extremities. Skin biopsy was consistent with EDP. The patient was started on topical halobetasol 0.05% ointment daily in conjunction with a 3-week prednisone taper as follows: 60 mg/d for 1 week, followed by 40 mg/d for 1 week, followed by 20 mg/d for 1 week. Significant improvement was noted after the prednisone taper. The patient was then transitioned to a 3-month course of isotretinoin as follows: 20 mg/d for 2 months followed by 10 mg/d for the final month. At the completion of treatment, there was no evidence of erythema or pigmentation. Two months after discontinuation of isotretinoin, the patient reported relapse but declined further treatment.

Case 4
A 54-year-old Hispanic woman with a history of diabetes and hypertension presented with multiple polycyclic hyperpigmented patches and surrounding erythematous borders coalescing on the medial aspect of the bilateral arms and forearms. Skin biopsy was consistent with EDP, and the patient was started on topical halobetasol 0.05% ointment daily in conjunction with a 3-week prednisone taper as follows: 60 mg/d for 1 week, followed by 40 mg/d for 1 week, followed by 20 mg/d for 1 week. At the completion of the prednisone taper, the affected areas were substantially improved with resolution of the surrounding erythematous borders. Thereafter, isotretinoin, 20 mg/d, was initiated. After only 1 month of isotretinoin, the patient discontinued treatment because of satisfaction with the clinical improvement, and reported no signs of relapse 2 months later.
DISCUSSION
Also known as ashy dermatosis, EDP is a chronic progressive hyperpigmentation disorder of unknown etiology, first described in 1957. EDP classically presents as asymptomatic, gray-to-blue patches with an erythematous border in a symmetrical distribution over the neck, trunk, and upper extremities. Histopathologic findings, although not specific, show variation depending on the stage of evolution. Acute or early inflammatory patches display basal vacuolar degeneration, papillary dermal edema, and perivascular lymphocytic inflammation. In contrast, chronic lesions show abundant melanophages and pigment incontinence, with diminished-to-absent inflammation, features that may be indistinguishable from postinflammatory hyperpigmentation of other causes.

To date, no randomized, placebo-controlled clinical trials have been conducted to determine standard therapeutic modalities and appropriate dosing regimens for the management of EDP. Some retrospective studies proposed numerous therapeutic agents, but results are inconsistent. Therapies reported from the years 2000 until now are summarized in Supplemental Table I. There is clearly an unmet need for consistently effective treatment. In this case series, we are the first, to our knowledge, to report a combination therapy of prednisone and isotretinoin in the early inflammatory stage of EDP.

As demonstrated in all cases presented, prednisone appears to both rapidly clear the erythematous border and improve the dyspigmentation, with significant improvement noted after only 3 weeks of treatment. The addition of isotretinoin appears to clear residual hyperpigmentation and maintain remission. Immune dysregulation in EDP is driven by interleukin-2, interferon-γ, natural killer cells, and cytotoxic CD8⁺ T cells, which may be modulated by prednisone and isotretinoin.

In this series no patient experienced significant adverse effects. Two of the 4 patients relapsed after stopping isotretinoin, which indicates that long-term treatment may be required to maintain remission. This finding mirrors the only previously reported case of EDP treated with isotretinoin in which the
patient experienced relapse within 2 months of stopping isotretinoin and required long-term isotretinoin to maintain remission. The specific treatment regimens used and patient characteristics from this series are summarized in Supplemental Table II. In our experience, for the combined effect of prednisone and isotretinoin to be maximally successful, EDP should be treated at its earliest inflammatory stage, which is represented by light grey-to-lilac patches with a surrounding erythematous border. We feel it is imperative to recognize EDP early and initiate treatment immediately to achieve optimal response.

Limitations of this series include a small sample size limited to only adult female Hispanic patients. Nonetheless, this observation provides insight for a readily available therapy that may improve pigmentation and arrest disease activity in a historically recalcitrant disorder. Larger, long-term observational or prospective studies are warranted to determine the optimal length of treatment to produce clinical resolution and prevent relapse.

REFERENCES
1. Kumarasinghe SPW, Pandya A, Chandran V, et al. A global consensus statement on ash dermatosis, erythema dyschromic perstans, lichen planus pigmentosus, idiopathic eruptive macular pigmentation, and Riehl's melanosis. Int J Dermatol. 2019;58:263-272.
2. Chang SE, Kim HW, Shin JM, et al. Clinical and histological aspect of erythema dyschromicum perstans in Korea: a review of 68 cases. J Dermatol. 2015;42:1053-1057.
3. Wolfshohl JA, Geddes ER, Stout AB, Friedman PM. Improvement of erythema dyschromicum perstans using a combination of the 1,550-nm erbium-doped fractionated laser and topical tacrolimus ointment. Lasers Surg Med. 2017;49:60-62.
4. Leung N, Oliveira M, Selim MA, McKinley-Grant L, Lesesky E. Erythema dyschromicum perstans: a case report and systematic review of histologic presentation and treatment. Int J Womens Dermatol. 2018;4:216-222.
5. Gutierrez D, Krueger LD, Tan A, Park JH, Lipkin G, Meehan SA. Proton pump inhibitor-induced erythema dyschromicum perstans-like pigmentation. JAAD Case Rep. 2019;5:701-703.
6. Tlougan BE, Gonzalez ME, Mandal RV, Kundu RV, Skopicki D. Erythema dyschromicum perstans. Dermatol Online J. 2010;16:17.
7. Tamer F. Coexistence of erythema dyschromicum perstans and vitiligo: a case report and review of the literature. Acta Dermato-venereal Alp Pannonica Adriat. 2016;25:77-78.
8. Cheng HM, Chuah SY, Gan EY, Jhingan A, Thng STG. A retrospective clinico-pathological study comparing lichen planus pigmentosus with ash dermatosis. Australas J Dermatol. 2018;59:322-327.
9. Wang F, Zhao YK, Wang Z, Liu JH, Luo DQ. Erythema dyschromicum perstans response to isotretinoin. JAMA Dermatol. 2016;152:841-842.
10. Osswald SS, Proffer LH, Sartori CR. Erythema dyschromicum perstans: a case report and review. Cutis. 2001;68:25-28.
11. Vasquez-Ochoa LA, Isaza-Guzman DM, Orozco-Mora B, Restrepo-Molina R, Trujillo-Perez J, Tapia FJ. Immunopathologic study of erythema dyschromicum perstans (ash dermatosis). Int J Dermatol. 2006;45:937-941.
12. Muthu SK, Narang T, Saikia UN, Kanwar AJ, Parsad D, Dogra S. Low-dose oral isotretinoin therapy in lichen planus pigmentosus: an open-label non-randomized prospective pilot study. Int J Dermatol. 2016;55:1048-1054.
SUPPLEMENTAL REFERENCES

S1. Cheng HM, Chuah SY, Gan EY, Jhingan A, Thng STG. A retrospective clinico-pathological study comparing lichen planus pigmentosus with ashy dermatosis. *Australas J Dermatol*. 2018;59:322-327.

S2. Leung N, Oliveira M, Selim MA, McKinley-Grant L, Lesesky E. Erythema dyschromicum perstans: a case report and systematic review of histologic presentation and treatment. *Int J Womens Dermatol*. 2018;4:216-222.

S3. Rato M, Monteiro AF, Arahan J, Tavares E. Ashy dermatosis with involvement of mucous membranes. *An Bras Dermatol*. 2017;92:17-20.

S4. Wolfshohl JA, Geddes ER, Stout AB, Friedman PM. Improvement of erythema dyschromicum perstans using a combination of the 1,550-nm erbium-doped fractionated laser and topical tacrolimus ointment. *Lasers Surg Med*. 2017;49:60-62.

S5. Wang F, Zhao YK, Wang Z, Liu JH, Luo DQ. Erythema dyschromicum perstans response to isotretinoin. *JAMA Dermatol*. 2016;152:841-842.

S6. Chang SE, Kim HW, Shin JM, et al. Clinical and histological aspect of erythema dyschromicum perstans in Korea: a review of 68 cases. *J Dermatol*. 2015;42:1053-1057.

S7. Mahajan VK, Chauhan PS, Mehta KS, Sharma AL. Erythema dyschromicum perstans: response to topical tacrolimus. *Indian J Dermatol*. 2015;60:525.

S8. Fabbrocini G, Cacciapuoti S, Izzo R, Mascolo M, Staibano S, Monfrecola G. Efficacy of narrowband UVB phototherapy in erythema dyschromicum perstans treatment: case reports. *Acta Dermatovenerol Croat*. 2015;23:63-65.

S9. Antonov NK, Braverman I, Subtil A, Halasz CL. Erythema dyschromicum perstans showing resolution in an adult. *JAAD Case Rep*. 2015;1:185-187.

S10. Kroon MW, Wind BS, Meesters AA, et al. Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. *J Dermatolog Treat*. 2012;23:339-344.

S11. Wind BS, Meesters AA, Kroon MW, et al. Formation of fibrosis after nonablative and ablative fractional laser therapy. *Dermatol Surg*. 2012;38:437-442.

S12. Imamishi H, Tsuruta D, Kobayashi H, Ishii M, Nakagawa K. Two cases of unilateral ashy dermatosis. *Case Rep Dermatol*. 2011;3:1-4.

S13. Tlougan BE, Gonzalez ME, Mandal RV, Kundu RV, Skopicki D. Erythema dyschromicum perstans. *Dermatol Online J*. 2010;16:17.

S14. Micciantuono SR, Cardona L, Pinzon-Plazas M, Rendon M. Erythema dyschromicum perstans: successful treatment with clofazimine under a single-patient investigational new drug study. *Cosmet Dermatol*. 2009;22:299-302.

S15. Bahadir S, Cobanoglu U, Cimsit G, Yayli S, Alpay K. Erythema dyschromicum perstans: response to dapsone therapy. *Int J Dermatol*. 2004;43:220-222.

S16. Osswald SS, Proffer LH, Sartori CR. Erythema dyschromicum perstans: a case report and review. *Culis*. 2001;68:25-28.

S17. Kontochristopoulos GI, Aroni K, Anagnostopoulos G, Nakopoulos L, Tassopoulos NC. Erythema dyschromicum perstans and hepatitis C virus infection. *Int J Dermatol*. 2001;40:346-348.
**Supplemental Table I. Summary of previous therapies used in erythema dyschromicum perstans**

| Year, Study | Study type | no, Sex | Age range (yr) | Ethnicity | Therapies used | Reported treatment outcomes |
|-------------|------------|---------|----------------|-----------|----------------|----------------------------|
| 2018,51     | Retrospective study | 26, NA | 16-65 | Asian | Topicals: steroid, hydroquinone, tacrolimus, tretinoin; oral steroid | Five showed improvement following combined topical hydroquinone and steroid; remaining showed stable disease at 0.5- to 3-mo follow-up |
| 2018,52     | Case report | 1 Male | 17 | NA | Narrow-band UVB, topical clobetasol and tacrolimus | Sustained resolution at 4-yr follow-up |
| 2017,53     | Case report | 1 Female | 57 | White | Clofazimine | No improvement |
| 2017,54     | Case report | 1 Female | 35 | NA | Fractionated nonablative laser and tacrolimus ointment | Improvement >75% and maintained at 5-mo follow-up |
| 2016,55     | Case report | 1 Male | 48 | Asian | Isotretinoin | Recurrence upon discontinuation of treatment. |
| 2015,56     | Retrospective study | 39 Female; 29 Male | 3-76 | Asian | Topicals: steroid, tretinoin, hydroquinone; dapsone, clofazimine, minocycline | Most exhibited no improvement or worsened progression at >1-yr follow-up |
| 2015,57     | Case report | 1 Female; 1 Male | 19, 29 | NA | Topical tacrolimus | Resolution following therapy with no recurrence at 2- to 3-mo follow-up |
| 2015,58     | Case report | 2 Female | 53, 59 | NA | Narrow-band UVB | Improvement noted |
| 2015,59     | Case report | 1 Female | 25 | Hispanic | Topical clobetasol, pimecrolimus, tacrolimus; dapsone | No response to therapies; self-resolution noted at 5-yr follow-up |
| 2012,510    | Preliminary study | 4 Female; 4 Male | 20-54 | NA | Nonablative fractional laser therapy | No improvement |
| 2012,511    | Randomized, observer-blinded study | 6, NA | NA | NA | Nonablative fractional laser therapy | No improvement |
| 2011,512    | Case report | 1 Female | 11, 21 | Asian | Q-switched ruby laser | No improvement |
| 2010,513    | Case report | 1 Male | 39 | Hispanic | Narrow-band UVB | Improvement following therapy |
| 2009,514    | Case report | 1 Female | 34 | NA | Clofazimine | Resolution following therapy |
| 2004,515    | Case report | 1 Male | 16 | NA | Dapsone | Resolution following therapy |
| 2001,516    | Case report | 1 Male | 21 | Hispanic | Prednisone | Improvement following therapy |
| 2001,517    | Case report | 1 Female | 48 | NA | Interferon-α and ribavirin | Improvement following therapy |

NA, Not available; UVB, ultraviolet B.
### Supplemental Table II. Clinical demographics and treatment outcomes

| No. | Age (yr) | Sex   | Ethnicity | Medical history              | Treatment regimen                                      | Treatment outcome                                      |
|-----|----------|-------|-----------|-----------------------------|---------------------------------------------------------|--------------------------------------------------------|
| 1   | 54       | Female| Hispanic  | Hypothyroidism              | Triamcinolone 0.1% cream 3-wk prednisone taper (60 mg: 40:20) 5-mo isotretinoin taper (40 mg: 20:20:20:10) | Complete resolution but with mild relapse after 16 mo |
| 2   | 47       | Female| Hispanic  | None                        | Halobetasol 0.05% ointment 3-wk prednisone taper (60 mg: 40:20) 4-mo isotretinoin taper (40 mg: 20:20:10) | Marked clinical improvement without recurrence at 24 mo |
| 3   | 54       | Female| Hispanic  | Sjogren syndrome, fibromyalgia | Halobetasol 0.05% ointment 3-wk prednisone taper (60 mg: 40:20) 3-mo isotretinoin taper (20 mg: 20:10) | Marked clinical improvement but with subjective recurrence at 2 mo |
| 4   | 54       | Female| Hispanic  | DM II, HTN                  | Halobetasol 0.05% ointment 3-wk prednisone taper (60 mg: 40:20) 1-mo isotretinoin, 20 mg/d | Complete resolution without recurrence at 2 mo |

*DM, Diabetes mellitus; HTN, hypertension.*